WO2011018582A2 - Microgranulés flottants - Google Patents
Microgranulés flottants Download PDFInfo
- Publication number
- WO2011018582A2 WO2011018582A2 PCT/FR2010/051691 FR2010051691W WO2011018582A2 WO 2011018582 A2 WO2011018582 A2 WO 2011018582A2 FR 2010051691 W FR2010051691 W FR 2010051691W WO 2011018582 A2 WO2011018582 A2 WO 2011018582A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- floating
- active ingredient
- granules
- alkaline agent
- granule
- Prior art date
Links
- 239000008187 granular material Substances 0.000 claims abstract description 121
- 239000007787 solid Substances 0.000 claims abstract description 32
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 62
- 239000004480 active ingredient Substances 0.000 claims description 54
- 239000011248 coating agent Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 21
- 239000011230 binding agent Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 230000002378 acidificating effect Effects 0.000 claims description 15
- 150000007513 acids Chemical class 0.000 claims description 13
- 229940035676 analgesics Drugs 0.000 claims description 10
- 239000000730 antalgic agent Substances 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- 229920001800 Shellac Polymers 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 9
- 239000004208 shellac Substances 0.000 claims description 9
- 235000013874 shellac Nutrition 0.000 claims description 9
- 229940113147 shellac Drugs 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 238000010410 dusting Methods 0.000 claims description 6
- 229920005862 polyol Polymers 0.000 claims description 6
- 150000003077 polyols Chemical class 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 125000005456 glyceride group Chemical group 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- -1 gums Chemical class 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- 239000011575 calcium Chemical class 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Chemical class 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical class [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 150000003109 potassium Chemical class 0.000 claims description 2
- 150000004760 silicates Chemical class 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 241000978776 Senegalia senegal Species 0.000 claims 1
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 claims 1
- 239000010410 layer Substances 0.000 description 17
- 238000000576 coating method Methods 0.000 description 16
- 239000002253 acid Substances 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 11
- 229920003134 Eudragit® polymer Polymers 0.000 description 10
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 235000003599 food sweetener Nutrition 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 238000005188 flotation Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 4
- 229960003883 furosemide Drugs 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 125000005395 methacrylic acid group Chemical group 0.000 description 2
- 239000008185 minitablet Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical group CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- JUAGNSFMKLTCCT-UHFFFAOYSA-N 2-aminoacetic acid;carbonic acid Chemical compound OC(O)=O.NCC(O)=O JUAGNSFMKLTCCT-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000012073 inactive phase Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004335 litholrubine BK Substances 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960005344 tiapride Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the subject of the present invention is floating microgranules, as well as their method of preparation.
- the oral route remains the path of choice and therefore the most used in the therapeutic field.
- the gastrointestinal tract has been modeled and studied according to various parameters (transit, pH, surface, presence of specific receptors or transporters). Depending on their intrinsic physicochemical characteristics, the active ingredients contained in the drug forms are absorbed at specific levels of the digestive tract.
- sustained release form delayed release form
- bioadhesive forms to control the duration and location of the release of the active ingredient.
- the international application WO 01/10417 describes a pharmaceutical composition in the form of a tablet floating in the stomach, consisting of an active phase comprising an active ingredient in combination with one or more excipients and an inactive phase comprising a system.
- gas generator CO 2
- a hydrophilic polymer or a porous mineral compound Preferably, said generating system comprises, in an intimate mixture, an alkali or alkaline earth metal carbonate or an alkali metal bicarbonate, in combination with an acid chosen in particular from mono- and polycarboxylic acids. This intimate blend forms an effervescent couple.
- International application WO 01/80822 relates to granules effervescent agents and their process of preparation. These granules consist of an effervescent couple and an extrudable binder hot melt.
- the effervescent couple is a combination of an acidic agent and an alkaline agent, which causes the formation of a gas in the presence of water.
- the formulations described in WO 01/80822 comprise an acidic agent / basic agent combination.
- International application WO 02/085336 relates to orodispersible tablets comprising at least one active ingredient, a mixture of excipients, effervescent granules consisting of a mixture of an acidic agent, an alkaline agent and an extrudable binder. hot. These tablets disintegrate in the oral cavity in contact with saliva in less than 60 seconds.
- Sheth and Tossounian describe a sustained release floating capsule based on the swelling of a cellulosic derivative in the presence of liquid.
- compositions listed above relate to tablets comprising an acid / base mixture for effervescence.
- the gastric emptying depends indeed on the nature, the volume, the size and the digestibility of the solid elements present in the stomach. Liquids but also solid particles with a diameter of less than 3-5 mm easily pass the pylorus and will be drained quickly during the digestive phase. This type of particles is a priori penalizing for the active ingredients absorbed very high in the digestive tract. For larger particles such as monolithic forms, they are retained by the pyloric barrier and will be drained only during the inter-digestive periods. Finally, depending on the time of day (fasting or postprandial period), the gastric transit for these monolithic forms will be much larger and may vary from a few tens of minutes to several hours.
- the tablet is problematic to get a good flotation of the drug form. It becomes necessary in this case to use a large amount of effervescent agent to obtain the desired flotation.
- the aforementioned Goole works consist in developing mini-tablets with a diameter of three millimeters but using an acid / base pair for effervescence.
- the present invention aims to provide a solution to all the aforementioned drawbacks.
- Another object of the invention is to provide a floating multiparticulate sustained release form, particularly useful for reducing the variability and therefore the reproducibility and to guard against the disadvantages observed with the monolithic forms that are capsules or tablets.
- Another object of the present invention is to provide a floating multiparticulate form preserving the wall of the stomach by reducing the risk of local intolerance.
- the present invention therefore consists in providing a composition specifically designed to obtain a drug form sufficiently titrated in active principle while keeping a sufficiently small size to obtain a satisfactory flotation, and more particularly for the active ingredients having a high absorption in the digestive tract.
- the present invention therefore relates to floating granules comprising a solid core on which an active ingredient is supported, said granules being characterized in that they also comprise a compound capable of generating a gas evolution consisting of an alkaline agent.
- the present invention therefore relates to floating granules comprising a solid core on which an active ingredient is supported, said granules being characterized in that they comprise only an alkaline agent as a compound capable of generating a gas evolution.
- the present invention therefore relates to floating granules comprising a solid core on which an active ingredient is supported, said granules being characterized in that they comprise an alkaline agent and in that they do not comprise an acidic agent as a compound likely to generate a gaseous release.
- Floating granules according to the invention are characterized in that they comprise, deposited on a support or solid core, at least one active principle, and in that they comprise an agent capable of generating a gassing consisting solely of a alkaline agent.
- the floating granules according to the invention therefore do not use an acidic agent / alkaline agent mixture as usually in the state of the art.
- the flotation is obtained by reaction of the acidic stomach fluid when it diffuses within the drug form.
- Floating granules according to the invention are able to float long enough in the stomach and the multilayer formulation further ensures prolonged diffusion of the active ingredient.
- the aforementioned alkaline agent can also be supported on said solid support.
- floating granules according to the invention comprise, supported on said solid core, at least one active ingredient and an alkaline agent which is capable of generating a gas evolution.
- the aforementioned alkaline agent can also be used directly as a carrier.
- floating granules according to the invention comprise, supported on a solid core consisting of an alkaline agent, at least one active ingredient.
- the alkaline agent is used as a solid core on which the active ingredients are supported or it is incorporated in the constituent layers of the granule, namely deposited on a solid support with the active ingredient (s) or present in a layer deposited on top of that formed by the active ingredient (s).
- the floating granules of the invention are therefore characterized in that they do not comprise an acidic agent capable of generating a gas evolution.
- acidic agent denotes any mineral or organic acid, in free acid form, acid anhydride or acid salt capable of generating gassing.
- the floating granules of the invention therefore do not comprise any acid carboxylic acid capable of generating a gassing (that is to say no mono- or polycarboxylic acid).
- the floating granules of the invention do not comprise an acidic agent in an amount sufficient to allow gassing.
- the floating granules of the invention are therefore preferably characterized in that they do not comprise an acid having a pH of less than or equal to 4.5 at room temperature.
- the floating granules of the invention preferably do not include tartaric acid, tartaric acid, citric acid, maleic acid, fumaric acid, malic acid, adipic acid, nor succinic acid, lactic acid, glycolic acid, alpha-hydroxy acid, nor ascorbic acid, nor amino acids, nor the salts and derivatives of these acids .
- the floating granules according to the present invention have a multilayer structure in which the active ingredient is deposited on a support and the other excipients are in turn deposited around this core.
- Floating granules according to the present invention are characterized in that the alkaline agent, used as a compound capable of generating a gas evolution, is not in contact with an acidic compound.
- the floating granules according to the invention comprise an acidic compound
- the alkaline agent and the acidic compound are separated by an intermediate layer.
- Floating granules according to the present invention are granules in which there is no direct contact between an acidic compound and the alkaline agent used as a compound capable of generating a gaseous release, or any other alkaline compound.
- the granules of the present invention comprise an acidic compound (as active ingredient or as an excipient)
- they then comprise films (or layers) intermediate between said acid and said alkaline agent to avoid any contact between them and therefore any reaction between them.
- These films (or intermediate layers) act as protective films to improve stability.
- the alkaline agent is deposited on the solid support: in such a case, the particles of active principle and of the alkaline agent are distributed indifferently on the support.
- the alkaline agent forms another layer independent of the layer formed by the active ingredient.
- the alkaline agent can therefore be incorporated at different levels of the granules. It can also be used directly as a granule carrier.
- granule refers to a preparation consisting of dry solid grains, each forming an aggregate of powder particles of sufficient strength to allow various manipulations.
- the granules are aggregates of crystallized or amorphous powders of various powders.
- the granules of the present invention are especially intended for oral administration, and more particularly to be swallowed as such.
- the granules of the present invention have a characteristic heart-bark structure, the heart not being of the same nature as the bark-forming compounds.
- these granules have a multilayer structure. Indeed, the active ingredient is deposited on the heart and thus forms a layer (or bark) deposited around the heart (or support).
- the heart of the granules can also be considered as being a support on which the particles of the active principle will be fixed.
- the heart consists of solid particles and the active ingredient supported by said heart is also in solid form.
- the present invention is therefore based on the development of a new multiparticulate oral form.
- the granules of the invention have a layer of active ingredient.
- this first layer may be covered by other polymeric layers using different coating polymers as well as the various adjuvants commonly used (plasticizers, solubilizers, lubricants, anti-adherents, etc.). These layers can therefore, as previously described, act as protective layers, avoiding the contact between the acidic and alkaline compounds.
- the floating granules of the invention comprise a solid core preferably chosen from insoluble supports, and more particularly chosen from the group consisting of polyols, gums, derivatives of silica, calcium or potassium derivatives, inorganic compounds such as dicalcium phosphates and tricalcium phosphates, sucrose, cellulose derivatives, especially microcrystalline cellulose, ethylcellulose and hydroxypropyl methylcellulose, starch, gluconates, silicates, sugar crystals, and mixtures thereof.
- insoluble supports preferably chosen from insoluble supports, and more particularly chosen from the group consisting of polyols, gums, derivatives of silica, calcium or potassium derivatives, inorganic compounds such as dicalcium phosphates and tricalcium phosphates, sucrose, cellulose derivatives, especially microcrystalline cellulose, ethylcellulose and hydroxypropyl methylcellulose, starch, gluconates, silicates, sugar crystals, and mixtures thereof.
- the solid core may consist of the alkaline agent.
- a particular family of granules according to the invention therefore consists of floating granules as defined above in which the active ingredient (s) are deposited on sodium bicarbonate
- the solid core of the granules may also consist of a mixture of compounds, especially a mixture of insoluble supports.
- a mixture of sucrose and starch or mineral compounds derived from silica or calcium may be mentioned.
- the solid core may also consist of soluble supports, among which may be mentioned certain solid grades of PEG (in particular PEG 4000 or PEG 6000).
- derived from silica refers to silica, and precipitated silicas obtained from alkali silicates, in particular Aerosil ®, or talc, bentonite or kaolin.
- calcium derivatives refers to crystalline excipients derived from calcium hydroxide, water insoluble products used in medicine as diluents, or fillers and also abrasives.
- potassium derivatives refers in particular to potassium bicarbonate and potassium chloride.
- magnesium derivatives in particular carbonates or oxides.
- the alkaline agent is chosen from the group consisting of carbonates and bicarbonates, and is especially chosen from the group consisting of sodium bicarbonate, sodium carbonate, glycine carbonate and sodium, potassium bicarbonate, magnesium carbonate, calcium carbonate and mixtures thereof.
- the granules of the invention may also comprise a binder.
- the role of the binder is to bind the particles together, that is to say, to perfect the cohesion of the granule.
- the binders make it possible to ensure good cohesion of the active ingredient and the core in the granules.
- the binders are, like the active ingredient, deposited around the heart of the granules.
- binders mention may be made of most of the hydrophilic excipients which give viscous solutions: gum arabic and tragacanth, methylcellulose and carboxymethylcellulose, gelatin, starches, maltodextrins, PEG 4000 and 6000 in alcoholic solution, polyvidone in aqueous or alcoholic solution, and also solutions of sucrose, glucose or sorbitol.
- the binders of the granules of the invention are preferably selected from the group consisting of starch, sucrose, gum arabic, polyvinylpyrrolidone (PVP or polyvidone), hydroxypropyl methylcellulose (HPMC), shellac , hydroxypropylcellulose (HPC), cellulose, polyols, polyglycolized glycerides (Gelucire ®) or macrogolglycerides, in particular stearoyl macrogolglycerides, also acrylic derivatives and mixtures thereof.
- polystylitol there may be mentioned in particular mannitol, sorbitol, maltitol or xylitol.
- the binders are preferably selected from the group consisting of polyvinylpyrrolidone, shellac, polyols, polyglycolized glycerides (Gelucire ®) or macrogolglycerides including macrogolglycerides stearoyl, as well as mixtures of them.
- binder chosen from the groups mentioned above for particular properties; for example, it may be useful to use pH-dependent excipients such as EUDRAGIT ® L100 or shellac as binder.
- coated granules consist of grains coated with one or more layers of mixtures of various excipients.
- the preferred coated granules according to the present invention comprise an additional layer consisting of the coating agent.
- the coating agents present in the granules of the invention are not acidic.
- the granules of the invention may also comprise a coating consisting of a coating agent chosen from the group consisting of wax derivatives, plasticizers (film-forming agents), shellac, polyvinylpyrrolidone, polyethylene glycol, cellulose derivatives such as HPMC or HPC, sucrose, glycerides of fatty acids and methacrylic polymers.
- a coating agent chosen from the group consisting of wax derivatives, plasticizers (film-forming agents), shellac, polyvinylpyrrolidone, polyethylene glycol, cellulose derivatives such as HPMC or HPC, sucrose, glycerides of fatty acids and methacrylic polymers.
- wax derivatives refers to natural or synthetic products consisting of esters of fatty acids and alcohols, generally solid at room temperature, used in various ways in drug preparations.
- the floating granules of the invention may also be coated with a coating film in which one or more excipients such as lubricants, colorants, sweeteners, plasticizers or anti-adhering agents are added.
- excipients such as lubricants, colorants, sweeteners, plasticizers or anti-adhering agents are added.
- the granules of the invention may also comprise an enteric coating, in particular consisting of methacrylic polymers, in particular Eudragit ® L, shellac or HPMCP (hydroxypropylmethylcellulose cellulosephtalate - hypromellose phthalate). Such granules are therefore gastro-resistant.
- enteric coating in particular consisting of methacrylic polymers, in particular Eudragit ® L, shellac or HPMCP (hydroxypropylmethylcellulose cellulosephtalate - hypromellose phthalate).
- enteric coating in particular consisting of methacrylic polymers, in particular Eudragit ® L, shellac or HPMCP (hydroxypropylmethylcellulose cellulosephtalate - hypromellose phthalate).
- This enteric coating can influence the bioavailability of the active ingredient, in particular by avoiding its degradation in an acidic medium.
- the floating granules of the invention may also comprise a coating for sustained release.
- Such granules allow a modified or delayed release of the active ingredients (modified release granules).
- Such a coating is obtained with coating agents in particular consist of copolymers of methacrylates and acrylates Eudragit ® S100,
- Eudragit ® RS Eudragit ® RL
- Eudragit ® RS Eudragit ® 3OD
- Eudragit ® RL30D shellac
- cellulose derivatives including ethylcellulose, waxes (including Gelucire ® ) and acrylic derivatives.
- Floating granules according to the present invention may also comprise a lubricant and / or an aroma and / or a sweetener and / or a colorant.
- talc magnesium stearate
- silica derivatives especially Aerosil ®
- waxes waxes
- sweeteners used in the context of the present invention are in particular those listed in Directive 94/35 / EC of 30 June 1994 concerning sweeteners for use in foodstuffs (as amended by Directive 2006/25 / EC of 5 July 2006).
- aspartame E 951, sorbitol E 420, mannitol E 421, acesulfame-K E 950, saccharin E 954, stevia or thaumatin there may be mentioned aspartame E 951, sorbitol E 420, mannitol E 421, acesulfame-K E 950, saccharin E 954, stevia or thaumatin.
- the dyes used in the context of the present invention are in particular those listed in Directive 95/45 / EC of 26 July 1995 on colorants that may be used in foodstuffs (as amended by Directive 2006/33 / EC of 20 March 2006). Thus, mention may especially be made of the dyes E 100 to E 180.
- the floating granules of the invention may comprise any active ingredient used in therapeutic pharmacy, as well as combinations thereof.
- the active ingredients used for the preparation of the floating granules of the invention are active ingredients with a narrow absorption window or absorbed high in the digestive tract.
- the active ingredients are not acidic compounds.
- active ingredients used for the preparation of floating granules according to the invention there may be mentioned in particular: furosemide, tiapride, alfuzosin, captopril, GHB or metformin.
- the active ingredient is not atenolol.
- active ingredients having a less specific absorption and non-exhaustively antiviral substances, antidepressant agents, cytostatic agents, hypocholesterolemic agents, analgesics, anti-inflammatory analgesics, diuretics and any other class therapeutic.
- the dosage form described herein is also of interest in the veterinary, nutraceutical, cosmetic and agricultural fields.
- analgesics help to eliminate the patient's pain.
- analgesics include central morphine analgesics (morphine derivatives), central non-morphine analgesics, peripheral analgesics and others such as benzodiazepines.
- the active ingredients of the granules according to the invention are chosen from the group consisting of nifedipine, morphine sulphate, oxycodone, gamma-hydroxybutyric acid or one of its salts, buprenorphine , modafinil, dextropropoxyphene, methadone, tramadol, nalbuphine, tetrahydrocannabinol and benzodiazepines.
- the floating granules according to the invention comprise from 0.5% to 60%, preferably from 15% to 50%, by weight of active ingredient relative to the total weight of the granule.
- the floating granules of the invention comprise from 15% to 70%, preferably from 25% to 50%, by weight of alkaline agent relative to the total weight of the granule.
- the floating granules of the invention are characterized in that the solid core represents from 20% to 80% by weight relative to the total weight of the granule.
- the floating granules according to the invention have a diameter of less than 3 mm.
- This size less than three millimeters ensures a good flotation in the stomach fluid.
- the small diameter of the granules of the invention and a fortiori their low mass, they can very easily float in the stomach fluid, and without requiring the presence of an excessive amount of compound likely to generate a gaseous release (alkaline agent).
- small pharmaceutical forms have the disadvantage of having a residence time too short in the stomach. It is therefore unexpected that the granules of the invention do not have this disadvantage. Indeed, these have a residence time in the stomach satisfactory because of their specific structure and chemical modifications performed (presence of 'insulating' layers between acids and bases).
- floating granules of the invention may also be called “floating microgranules”.
- the present invention also relates to a method for preparing floating granules as defined above, characterized in that it comprises a step of application by dusting of the active ingredient on a solid particulate support.
- the method also includes a step of adding the alkaline agent.
- the alkaline agent is added directly in admixture with the active ingredient and powdered on the support.
- Such a process therefore consists in applying the active ingredient and the alkaline agent by powdering on a solid particulate support.
- the alkaline agent is used as a solid support.
- a method therefore consists in applying by powdering the active ingredient on the alkaline agent constituting a solid particulate support.
- the method of the invention may also comprise, after the dusting step, a step of coating the granule, in particular by coating the coating agent in the form of a film on the granule, followed, where appropriate, by a coating. step of mixing with a lubricant and / or a flavor and / or a sweetener and / or a colorant.
- the structure of the granules of the invention is related to the implementation of this particular method which allows the production of granules of heart-shell structure.
- the above-mentioned powdering step of the process for the preparation of the granules of the invention may also comprise a step of spraying an alcoholic or aqueous-alcoholic or aqueous solution of a binder.
- This spraying step and the dusting step are preferably carried out simultaneously or alternately.
- the above-mentioned dusting step is carried out concomitantly with a step of spraying a binder in the form of a solution.
- An advantageous implementation of the process of the invention thus consists in applying the active ingredient, mixed or not with the alkaline agent, in powder form to the aforementioned particulate support (or core of the granules) by alternating binder as a solution.
- the method of the invention may also comprise, after the dusting step, one or more coating steps of the granule, in particular by coating the coating agent (s) in the form of films on the granule.
- a preferred embodiment of the process of the invention consists of a process comprising, after the coating step, a step of mixing with a lubricant and / or a flavor and / or a sweetener and / or a colorant, these they can themselves be prepared in the form of granules in order to be finally mixed with the active granules.
- a step of powder mounting of the furosemide active ingredient on the neutral supports was carried out with intermittent spraying of an alcoholic solution of the PVP binder.
- a second coating of the granules was carried out with an aqueous suspension comprising a plasticizer (dibutyl sebacate) and the agent Aquacoat ® EC30D coating system.
- a plasticizer dibutyl sebacate
- the agent Aquacoat ® EC30D coating system was carried out with an aqueous suspension comprising a plasticizer (dibutyl sebacate) and the agent Aquacoat ® EC30D coating system.
- an aqueous suspension containing the active ingredient (MOR 920) and the binder (HPMC) was prepared.
- a step of powder mounting of the furosemide active ingredient on the mannitol support (Pearlitol 400 DC, Roquette) was carried out with an intermittent spraying of an alcoholic solution of the binder (shellac - GLDB).
- the granules were then dried in a fluidized air bed.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Glanulating (AREA)
- Manufacture Of Metal Powder And Suspensions Thereof (AREA)
Abstract
Description
Claims
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1864DEN2012 IN2012DN01864A (fr) | 2009-08-12 | 2010-08-11 | |
ES10761038.8T ES2588430T3 (es) | 2009-08-12 | 2010-08-11 | Microgránulos flotantes |
DK10761038.8T DK2464333T3 (en) | 2009-08-12 | 2010-08-11 | Liquid microgranules |
AU2010283608A AU2010283608B9 (en) | 2009-08-12 | 2010-08-11 | Floating microgranules |
JP2012524262A JP6068142B2 (ja) | 2009-08-12 | 2010-08-11 | 浮遊微粒剤 |
SI201031271A SI2464333T1 (sl) | 2009-08-12 | 2010-08-11 | Plavajoče mikrogranule |
CA2771053A CA2771053C (fr) | 2009-08-12 | 2010-08-11 | Microgranules flottants |
BR112012003289-5A BR112012003289B1 (pt) | 2009-08-12 | 2010-08-11 | Granulado do tipo nucleo-casca |
SM201600347T SMT201600347B (it) | 2009-08-12 | 2010-08-11 | Microgranuli flottanti |
EA201200269A EA023532B1 (ru) | 2009-08-12 | 2010-08-11 | Флотирующие микрогранулы |
US13/390,217 US8916202B2 (en) | 2009-08-12 | 2010-08-11 | Floating microgranules |
EP10761038.8A EP2464333B1 (fr) | 2009-08-12 | 2010-08-11 | Microgranulés flottants |
SG2012009965A SG180305A1 (en) | 2009-08-12 | 2010-08-11 | Floating microgranules |
CN201080044056.7A CN102548541B (zh) | 2009-08-12 | 2010-08-11 | 漂浮微颗粒剂 |
MX2012001878A MX2012001878A (es) | 2009-08-12 | 2010-08-11 | Microgranulos flotantes. |
KR1020177030037A KR20170119743A (ko) | 2009-08-12 | 2010-08-11 | 유동성 마이크로과립체 |
LTEP10761038.8T LT2464333T (lt) | 2009-08-12 | 2010-08-11 | Plūduriuojančios mikrogranulės |
NZ598468A NZ598468A (en) | 2009-08-12 | 2010-08-11 | Floating microgranules |
UAA201202667A UA107361C2 (en) | 2009-08-12 | 2010-11-08 | Floating microgranules |
IL218072A IL218072A (en) | 2009-08-12 | 2012-02-13 | Floating microgranules |
TNP2012000068A TN2012000068A1 (fr) | 2009-08-12 | 2012-02-13 | Microgranules flottants |
MA34624A MA33523B1 (fr) | 2009-08-12 | 2012-02-13 | Microgranulés flottants |
ZA2012/01711A ZA201201711B (en) | 2009-08-12 | 2012-03-08 | Floating microgranules |
HK12113624.3A HK1172824A1 (en) | 2009-08-12 | 2012-12-31 | Floating microgranules |
HRP20161149TT HRP20161149T1 (hr) | 2009-08-12 | 2016-09-06 | Plutajuće mikrogranule |
CY20161100954T CY1118119T1 (el) | 2009-08-12 | 2016-09-26 | Επιπλεοντα μικροκοκκια |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0955641A FR2949061B1 (fr) | 2009-08-12 | 2009-08-12 | Microgranules flottants |
FR0955641 | 2009-08-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011018582A2 true WO2011018582A2 (fr) | 2011-02-17 |
WO2011018582A3 WO2011018582A3 (fr) | 2011-05-19 |
Family
ID=42115979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2010/051691 WO2011018582A2 (fr) | 2009-08-12 | 2010-08-11 | Microgranulés flottants |
Country Status (35)
Country | Link |
---|---|
US (1) | US8916202B2 (fr) |
EP (1) | EP2464333B1 (fr) |
JP (1) | JP6068142B2 (fr) |
KR (2) | KR20120050477A (fr) |
CN (1) | CN102548541B (fr) |
AR (1) | AR077864A1 (fr) |
AU (1) | AU2010283608B9 (fr) |
BR (1) | BR112012003289B1 (fr) |
CA (1) | CA2771053C (fr) |
CL (1) | CL2012000376A1 (fr) |
CY (1) | CY1118119T1 (fr) |
DK (1) | DK2464333T3 (fr) |
EA (1) | EA023532B1 (fr) |
ES (1) | ES2588430T3 (fr) |
FR (1) | FR2949061B1 (fr) |
HK (1) | HK1172824A1 (fr) |
HR (1) | HRP20161149T1 (fr) |
HU (1) | HUE030027T2 (fr) |
IL (1) | IL218072A (fr) |
IN (1) | IN2012DN01864A (fr) |
LT (1) | LT2464333T (fr) |
MA (1) | MA33523B1 (fr) |
MX (1) | MX2012001878A (fr) |
NZ (1) | NZ598468A (fr) |
PE (1) | PE20120805A1 (fr) |
PL (1) | PL2464333T3 (fr) |
PT (1) | PT2464333T (fr) |
SG (1) | SG180305A1 (fr) |
SI (1) | SI2464333T1 (fr) |
SM (1) | SMT201600347B (fr) |
TN (1) | TN2012000068A1 (fr) |
TW (1) | TWI478731B (fr) |
UA (1) | UA107361C2 (fr) |
WO (1) | WO2011018582A2 (fr) |
ZA (1) | ZA201201711B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11666546B2 (en) | 2017-12-18 | 2023-06-06 | Tris Pharma, Inc | GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
ES2562878T3 (es) | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
FR2938431B1 (fr) | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | Nouvelle composition a base d'acide gamma-hydroxybutyrique |
FR2949062B1 (fr) | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
US9321956B2 (en) | 2012-11-28 | 2016-04-26 | Halliburton Energy Services, Inc. | Methods for hindering the settling of particulates in a subterranean formation |
US9790774B2 (en) | 2014-01-02 | 2017-10-17 | Halliburton Energy Services, Inc. | Generating and maintaining conductivity of microfractures in tight formations by generating gas and heat |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
US10301917B2 (en) | 2015-07-24 | 2019-05-28 | Halliburton Energy Services, Inc. | Microbubbles for treatment chemical delivery in subterranean formations |
US10626321B2 (en) | 2015-07-24 | 2020-04-21 | Halliburton Energy Services, Inc. | Microbubbles for heat and/or gas generation in subterranean formations |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
EP3740189A1 (fr) * | 2017-12-18 | 2020-11-25 | Tris Pharma, Inc. | Composition de poudre de médicament à libération modifiée comprenant des systèmes de formation de raft de rétention gastrique ayant une libération de médicament par impulsions de déclenchement |
JP2022522270A (ja) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物 |
NL2024652B1 (en) * | 2020-01-10 | 2021-09-07 | Stabican B V | Process for preparing cannabinoid-containing particles |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
WO2001010417A1 (fr) | 1999-08-06 | 2001-02-15 | Galenix Developpement | Composition pharmaceutique flottante comprenant une phase active et une phase non active |
WO2001080822A2 (fr) | 2000-04-20 | 2001-11-01 | Ethypharm | Granules effervescents et techniques de preparation |
WO2002085336A1 (fr) | 2001-04-20 | 2002-10-31 | Ethypharm | Comprimes effervescents orodispersibles |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5276418A (en) * | 1975-12-19 | 1977-06-27 | Microbial Chem Res Found | Method of preparing foamable micro-capsule preparations |
US4101650A (en) * | 1977-04-06 | 1978-07-18 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pepstatin floating minicapsules |
JPS62195323A (ja) * | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | 胃内滞留型粒子 |
IT1217783B (it) | 1988-06-03 | 1990-03-30 | Farmaceutico Ct S R L Lab | Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative |
IT1248588B (it) | 1991-06-28 | 1995-01-19 | Gaetano Crepaldi | Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari. |
IT1266565B1 (it) | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
US5824339A (en) | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
US6214386B1 (en) * | 1995-11-22 | 2001-04-10 | Recordati, S.A. | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions |
US5846971A (en) | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
DE19630035A1 (de) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
FR2762213B1 (fr) * | 1997-04-18 | 1999-05-14 | Synthelabo | Composition pharmaceutique a retention gastrique |
SE9702533D0 (sv) * | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
JP3447042B2 (ja) | 1997-07-23 | 2003-09-16 | フロイント産業株式会社 | 単一物質球形粒の製造方法 |
US20050244497A1 (en) * | 1997-11-05 | 2005-11-03 | Wockhardt Limited | Delayed delivery system for acid-sensitive drugs |
US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
FR2784583B1 (fr) * | 1998-10-16 | 2002-01-25 | Synthelabo | Composition pharmaceutique a residence gastrique et a liberation controlee |
ES2193777T3 (es) | 1998-12-23 | 2003-11-01 | Orphan Medical Inc | Disoluciones estables e inalterables microbiologicamente de sal de gamma-hidroxibutirato para el tratamiento de la narcolepsia. |
AU2002319774B2 (en) | 2001-08-06 | 2005-04-21 | Euro-Celtique S.A. | Compositions and methods to prevent abuse of opioids |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US20030059397A1 (en) | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
FR2829932B1 (fr) | 2001-09-21 | 2006-11-24 | Ellipse Pharmaceuticals | Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu |
CA2409552A1 (fr) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Forme posologique orale pouvant etre retenue dans l'estomac dont la liberation est limitee a la partie inferieure du tube digestif |
EP1536774A1 (fr) | 2002-09-04 | 2005-06-08 | Ranbaxy Laboratories Limited | Formes dosifiees a gout masque, et leurs procedes de preparation |
EP1551372B8 (fr) | 2002-09-20 | 2018-08-01 | Alpharma Pharmaceuticals LLC | Sous-unite de sequestration et compositions et procedes associes |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
WO2005092297A2 (fr) | 2004-03-03 | 2005-10-06 | Teva Pharmaceutical Industries Ltd. | Composition pharmaceutique stable comprenant un medicament labile en milieu acide |
TW200533391A (en) * | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
US8193211B2 (en) | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
NZ561375A (en) | 2005-06-27 | 2011-06-30 | Biovail Lab Int Srl | Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound |
HUE053838T2 (hu) * | 2005-08-24 | 2021-07-28 | Endo Pharmaceuticals Inc | Nyújtott felszabadulású nabulfin-készítmények |
US20070092565A1 (en) * | 2005-10-25 | 2007-04-26 | Pharmascience Inc. | Gastric retention drug delivery system |
US9125833B2 (en) | 2005-11-02 | 2015-09-08 | Relmada Therapeutics, Inc. | Multimodal abuse resistant and extended release opioid formulations |
CA2633825A1 (fr) * | 2005-12-20 | 2007-07-05 | Teva Pharmaceutical Industries Ltd. | Comprimes de lansoprazole se desintegrant oralement |
FR2898056B1 (fr) | 2006-03-01 | 2012-01-20 | Ethypharm Sa | Comprimes resistant a l'ecrasement destines a eviter le detournement illicite |
MX2010001071A (es) * | 2007-07-27 | 2010-03-09 | Depomed Inc | Formas de dosificacion retentivas gastricas pulsatiles. |
JP5714910B2 (ja) | 2008-01-09 | 2015-05-07 | チャールストン ラボラトリーズ,インコーポレイテッド | 薬学的組成物 |
FR2938431B1 (fr) | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | Nouvelle composition a base d'acide gamma-hydroxybutyrique |
FR2949062B1 (fr) | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
-
2009
- 2009-08-12 FR FR0955641A patent/FR2949061B1/fr not_active Expired - Fee Related
-
2010
- 2010-08-11 WO PCT/FR2010/051691 patent/WO2011018582A2/fr active Application Filing
- 2010-08-11 KR KR1020127006333A patent/KR20120050477A/ko active Application Filing
- 2010-08-11 US US13/390,217 patent/US8916202B2/en active Active
- 2010-08-11 AU AU2010283608A patent/AU2010283608B9/en active Active
- 2010-08-11 TW TW099126758A patent/TWI478731B/zh active
- 2010-08-11 PL PL10761038.8T patent/PL2464333T3/pl unknown
- 2010-08-11 IN IN1864DEN2012 patent/IN2012DN01864A/en unknown
- 2010-08-11 CA CA2771053A patent/CA2771053C/fr active Active
- 2010-08-11 BR BR112012003289-5A patent/BR112012003289B1/pt active IP Right Grant
- 2010-08-11 JP JP2012524262A patent/JP6068142B2/ja active Active
- 2010-08-11 PE PE2012000216A patent/PE20120805A1/es not_active Application Discontinuation
- 2010-08-11 EP EP10761038.8A patent/EP2464333B1/fr active Active
- 2010-08-11 NZ NZ598468A patent/NZ598468A/en unknown
- 2010-08-11 HU HUE10761038A patent/HUE030027T2/en unknown
- 2010-08-11 DK DK10761038.8T patent/DK2464333T3/en active
- 2010-08-11 CN CN201080044056.7A patent/CN102548541B/zh active Active
- 2010-08-11 LT LTEP10761038.8T patent/LT2464333T/lt unknown
- 2010-08-11 PT PT107610388T patent/PT2464333T/pt unknown
- 2010-08-11 MX MX2012001878A patent/MX2012001878A/es active IP Right Grant
- 2010-08-11 SG SG2012009965A patent/SG180305A1/en unknown
- 2010-08-11 SI SI201031271A patent/SI2464333T1/sl unknown
- 2010-08-11 ES ES10761038.8T patent/ES2588430T3/es active Active
- 2010-08-11 KR KR1020177030037A patent/KR20170119743A/ko not_active Application Discontinuation
- 2010-08-11 EA EA201200269A patent/EA023532B1/ru not_active IP Right Cessation
- 2010-08-11 SM SM201600347T patent/SMT201600347B/it unknown
- 2010-08-12 AR ARP100102964A patent/AR077864A1/es unknown
- 2010-11-08 UA UAA201202667A patent/UA107361C2/ru unknown
-
2012
- 2012-02-13 TN TNP2012000068A patent/TN2012000068A1/fr unknown
- 2012-02-13 IL IL218072A patent/IL218072A/en active IP Right Grant
- 2012-02-13 CL CL2012000376A patent/CL2012000376A1/es unknown
- 2012-02-13 MA MA34624A patent/MA33523B1/fr unknown
- 2012-03-08 ZA ZA2012/01711A patent/ZA201201711B/en unknown
- 2012-12-31 HK HK12113624.3A patent/HK1172824A1/xx unknown
-
2016
- 2016-09-06 HR HRP20161149TT patent/HRP20161149T1/hr unknown
- 2016-09-26 CY CY20161100954T patent/CY1118119T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
WO2001010417A1 (fr) | 1999-08-06 | 2001-02-15 | Galenix Developpement | Composition pharmaceutique flottante comprenant une phase active et une phase non active |
WO2001080822A2 (fr) | 2000-04-20 | 2001-11-01 | Ethypharm | Granules effervescents et techniques de preparation |
WO2002085336A1 (fr) | 2001-04-20 | 2002-10-31 | Ethypharm | Comprimes effervescents orodispersibles |
Non-Patent Citations (1)
Title |
---|
GOOLE, INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 334, 2007, pages 35 - 41 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11666546B2 (en) | 2017-12-18 | 2023-06-06 | Tris Pharma, Inc | GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2464333B1 (fr) | Microgranulés flottants | |
EP2349217B1 (fr) | Granulé d'acide gamma-hydroxybutyrique | |
CA2825053C (fr) | Granules effervescents d'acide gamma-hydroxybutyrique | |
EP1976492B2 (fr) | Système d'administration de médicaments comprenant des médicaments faiblement basiques et des acides organiques | |
EP2464342B1 (fr) | Formulations pharmaceutiques contre le mésusage des médicaments | |
ES2739888T3 (es) | Composiciones y comprimidos farmacéuticos con recubrimiento compresible y métodos de fabricación | |
EP2605757B1 (fr) | Formulations a base de nalbuphine et leurs utilisations | |
BE1015217A5 (fr) | ||
US20100047343A1 (en) | Multiparticulate formulation having tramadol in immediate and controlled release form | |
EP1365751B1 (fr) | Granules et granules enrobes au gout masque | |
EP0216743A2 (fr) | Nouvelles formes galéniques du vérapamil, leur fabrication et médicaments contenant ces nouvelles formes galéniques | |
EP1646379B1 (fr) | Nouvelle composition pharmaceutique solide comprenant de l amisulpride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080044056.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10761038 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012000376 Country of ref document: CL Ref document number: 2771053 Country of ref document: CA Ref document number: 2012524262 Country of ref document: JP Ref document number: 218072 Country of ref document: IL Ref document number: MX/A/2012/001878 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000216-2012 Country of ref document: PE Ref document number: 12012500319 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1864/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010761038 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010283608 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201200269 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20127006333 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2010283608 Country of ref document: AU Date of ref document: 20100811 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13390217 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012003289 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012003289 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120213 |